U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H23NO7P2
Molecular Weight 319.2289
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IBANDRONIC ACID

SMILES

CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=MPBVHIBUJCELCL-UHFFFAOYSA-N
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)

HIDE SMILES / InChI
Molecular Formula C9H23NO7P2
Molecular Weight 319.2289
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Ibandronic acid (INN) or ibandronate sodium (USAN) is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug. Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers. In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint and/or muscle pain.[4] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. Ibandronic acid is marketed under the trade names Boniva in the USA, Bondronat in Europe, Bonviva in Asia, Ibandrix in Ecuador and Bondrova in Bangladesh.

Originator

Approval Year

2003
176
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Boniva

Approved Use

Unknown
Primary
Approved
8429
Boniva

Approved Use

Unknown
Primary
Approved
8429
Boniva

Approved Use

Directions: Acne Clearing Cleanser Acne Clearing Tonic Acne Clearing Treatment 101
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
90.64 ng/mL
EXPERIMENT
https://synapse.koreamed.org/Synapse/Data/PDFData/1179TCP/tcp-22-22.pdf
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBANDRONIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
549.24 ng × h/mL
EXPERIMENT
https://synapse.koreamed.org/Synapse/Data/PDFData/1179TCP/tcp-22-22.pdf
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBANDRONIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
32.38 h
EXPERIMENT
https://synapse.koreamed.org/Synapse/Data/PDFData/1179TCP/tcp-22-22.pdf
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBANDRONIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / month multiple, oral
Dose: 100 mg, 1 times / month
Route: oral
Route: multiple
Dose: 100 mg, 1 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/28389932
unhealthy, 55–74 years
n = 183
Health Status: unhealthy
Condition: osteoporosis
Age Group: 55–74 years
Sex: M+F
Population Size: 183
Sources:
https://pubmed.ncbi.nlm.nih.gov/28389932
Sources:
https://pubmed.ncbi.nlm.nih.gov/28389932
2.5 mg 1 times / day multiple, oral
Recommended
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
unhealthy, adult
n = 465
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 465
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (NOS) (4%)
Musculoskeletal disorder NOS (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
2 mg 1 times / 2 months multiple, intravenous
Dose: 2 mg, 1 times / 2 months
Route: intravenous
Route: multiple
Dose: 2 mg, 1 times / 2 months
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
unhealthy, adult
n = 442
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 442
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (NOS) (4%)
Musculoskeletal disorder NOS (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
3 mg 1 times / 3 months multiple, intravenous
Dose: 3 mg, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 3 mg, 1 times / 3 months
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
unhealthy, adult
n = 458
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 458
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
Disc. AE: Gastrointestinal disorder (NOS), Musculoskeletal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (NOS) (4%)
Musculoskeletal disorder NOS (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Other AEs: Agranulocytosis, Acute pancreatitis...
Other AEs:
Agranulocytosis (serious, 1 patient)
Acute pancreatitis (serious, 1 patient)
Acute pyelonephritis (serious, 1 patient)
Sepsis (serious, 1 patient)
Concussion (serious, 1 patient)
Poisoning (serious, 1 patient)
Follicle centre lymphoma diffuse small cell lymphoma (serious, 1 patient)
Malignant tongue neoplasm (serious, 1 patient)
Transient ischaemic attack (serious, 1 patient)
Pulmonary embolism (serious, 1 patient)
Deep vein thrombosis (serious, 2 patients)
Influenza (below serious, 4 patients)
Arthralgia (below serious, 8 patients)
Rheumatoid arthritis (below serious, 4 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
Other AEs: Death, Syncope...
Other AEs:
Death (serious, 1 patient)
Syncope (serious, 2 patients)
Pneumonia (serious, 1 patient)
Retinal detachment (serious, 1 patient)
Rectal haemorrhage (serious, 1 patient)
Pneumoconiosis (serious, 1 patient)
Nasopharyngitis (below serious, 7 patients)
Nausea (below serious, 4 patients)
Upper respiratory tract infection (below serious, 3 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
AEs

AEs

AESignificanceDosePopulation
Musculoskeletal disorder NOS 1%
Disc. AE
2.5 mg 1 times / day multiple, oral
Recommended
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
unhealthy, adult
n = 465
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 465
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
Gastrointestinal disorder (NOS) 4%
Disc. AE
2.5 mg 1 times / day multiple, oral
Recommended
Dose: 2.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
unhealthy, adult
n = 465
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 465
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
Musculoskeletal disorder NOS 2%
Disc. AE
2 mg 1 times / 2 months multiple, intravenous
Dose: 2 mg, 1 times / 2 months
Route: intravenous
Route: multiple
Dose: 2 mg, 1 times / 2 months
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
unhealthy, adult
n = 442
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 442
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
Gastrointestinal disorder (NOS) 4%
Disc. AE
2 mg 1 times / 2 months multiple, intravenous
Dose: 2 mg, 1 times / 2 months
Route: intravenous
Route: multiple
Dose: 2 mg, 1 times / 2 months
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
unhealthy, adult
n = 442
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 442
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
Musculoskeletal disorder NOS 2%
Disc. AE
3 mg 1 times / 3 months multiple, intravenous
Dose: 3 mg, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 3 mg, 1 times / 3 months
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
unhealthy, adult
n = 458
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 458
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
Gastrointestinal disorder (NOS) 4%
Disc. AE
3 mg 1 times / 3 months multiple, intravenous
Dose: 3 mg, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 3 mg, 1 times / 3 months
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
unhealthy, adult
n = 458
Health Status: unhealthy
Condition: postmenopausal osteoporosis
Age Group: adult
Sex: F
Population Size: 458
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf
Page: p. 24
Influenza below serious, 4 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Rheumatoid arthritis below serious, 4 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Arthralgia below serious, 8 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Acute pancreatitis serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Acute pyelonephritis serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Agranulocytosis serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Concussion serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Follicle centre lymphoma diffuse small cell lymphoma serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Malignant tongue neoplasm serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Poisoning serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Pulmonary embolism serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Sepsis serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Transient ischaemic attack serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Deep vein thrombosis serious, 2 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
unhealthy
n = 70
Health Status: unhealthy
Condition: Osteoporosis
Sex: F
Population Size: 70
Sources:
https://clinicaltrials.gov/ct2/show/NCT00545051
Upper respiratory tract infection below serious, 3 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
Nausea below serious, 4 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
Nasopharyngitis below serious, 7 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
Death serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
Pneumoconiosis serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
Pneumonia serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
Rectal haemorrhage serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
Retinal detachment serious, 1 patient
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
Syncope serious, 2 patients
150 mg 1 times / month multiple, oral
Dose: 150 mg, 1 times / month
Route: oral
Route: multiple
Dose: 150 mg, 1 times / month
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
unhealthy
n = 86
Health Status: unhealthy
Condition: Osteoporosis
Sex: M
Population Size: 86
Sources:
https://clinicaltrials.gov/ct2/show/NCT00397839
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587

substrate
1737
inhibitor
1767

substrate
1037
inhibitor
1852

substrate
1217
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2A6
707

CYP2C19
1478

CYP2E1
882
CYP1A2
1054

CYP2A6
543

CYP2C19
991

CYP2E1
667
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP2A6
739
 no
CYP2C19
1553
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP2E1
970
 no
CYP3A4
1925
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1054
 no
CYP2A6
543
 no
CYP2C19
991
 no
CYP2C9
1037
 no
CYP2D6
1217
 no
CYP2E1
667
 no
CYP3A4
1737
 no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-1493
http://www.3bsc.com/index/pro_info.php?id=55209
AA Blocks
AA000AF6
http://www.aablocks.com/goods/Goods/detail?id=AA000AF6
AEchem Scientific Corp., USA
AE032312
http://www.aechemsc.com/info_products/AE032312.php
AHH Chemical co.,ltd
MT-01142
http://www.ahhchemical.com/product/MT-01142.html
AK Scientific, Inc. (AKSCI)
71724
http://www.aksci.com/item_detail.php?cat=71724
Acadechem
ACDS-026262
http://www.acadechemical.com/product/100961
Achemtek
0104-008135
http://www.achemtek.com/114084-78-5
Angene
AGN-PC-04XVIP
http://www.angenechemical.com/productshow/AGN-PC-04XVIP.html
Aurora Fine Chemicals LLC
A13.112.890
http://online.aurorafinechemicals.com/info?ID=A13.112.890
Aurum Pharmatech LLC
M-1207
http://www.Aurumpharmatech.com/Product/ProductDetails/M_1207
AvaChem Scientific
2445A
http://www.avachem.com/productSearch.asp?2445A
BLD Pharm
BD17613
http://www.bldpharm.com/products/114084-78-5.html
BioChemPartner
BCP13798
http://www.biochempartner.com/114084-78-5-BCP13798
BioSynth
J-003052
https://www.biosynth.com/en/products/all-products/products/J-003052.html
Boerchem
BC219057
http://www.boerchem.com/?product_36883.html
CSNpharm
CSN12493
https://www.csnpharm.com/products/ibandronate.html
Chem Scene
CS-2726
http://www.chemscene.com/114084-78-5.html
ChemMol
30108986
http://www.chemmol.com/chemmol/30108986.html
ChemMol
44005823
http://www.chemmol.com/chemmol/44005823.html
ChemMol
49409545
http://www.chemmol.com/chemmol/49409545.html
ChemMol
81411772
http://www.chemmol.com/chemmol/81411772.html
Chemspace
CSSB00000036762
https://chem-space.com/CSSB00000036762
Clearsynth
CS-O-01646
http://www.clearsynth.com/en/CSO01646.html
Clearsynth
CS-BU-00048
https://www.clearsynth.com/en/CSBU00048.html
Clearsynth
CS-O-30604
https://www.clearsynth.com/en/CSO30604.html
Finetech
FT-0670253
http://www.finetechnology-ind.com/prod/detail/pub/1130899-41-0.html
Finetech
FT-0602640
http://www.finetechnology-ind.com/prod/detail/pub/114084-78-5.html
Hefei Hirisun Pharmatech Co., Ltd
HR130939
http://hirisunpharm.com/114084-78-5.html
Matrix Scientific
100579
https://www.matrixscientific.com/100579.html
MedChem Express
HY-B0515A
https://www.medchemexpress.com/Ibandronic-acid.html
MuseChem
I000530
https://www.musechem.com/product/I000530.html
OChem
7534
http://www.ocheminc.com/index.php?act=psearch&pid=084I785
Sinfoo Biotech
S010605
http://www.sinfoobiotech.com/product/1014003
Smolecule
S594667
https://www.smolecule.com/products/s594667
THE BioTek
bt-300824
https://www.thebiotek.com/product/others/bt-300824
Yuhao Chemical
RT16287
http://www.chemyuhao.com/114084-78-5.html
abcr GmbH
AB506647
http://www.abcr.com/shop/en/AB506647
iChemical
EBD38131
http://www.ichemical.com/chemicals/cas-114084-78-5
PubMed

PubMed

TitleDatePubMed
New insights into the molecular mechanisms of action of bisphosphonates.
2003
[Effects of ibandronate on the osteopenia process in tail-suspended rats].
2003
Bisphosphonates in the management of metastatic prostate cancer.
2003
Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.
2003
Drugs in development: bisphosphonates and metalloproteinase inhibitors.
2003
The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
2003 Apr
Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.
2003 Apr 22
Collagen crosslink excretion and staging of oral cancer.
2003 Apr 7
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years.
2003 Aug
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
2003 Aug
Oral weekly ibandronate prevents bone loss in postmenopausal women.
2003 Aug
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
2003 Aug
Is ibandronate effective in multiple myeloma?
2003 Dec
[Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
2003 Dec
Injectable drug dampens bone loss.
2003 Dec
Bone resorption predicts for skeletal complications in metastatic bone disease.
2003 Dec 1
[How to treat tumor-induced hypercalcemia].
2003 Dec 15
Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate.
2003 Jul
The bisphosphonate ibandronate stimulates reverse cholesterol transport out of monocytoid cells by enhanced ABCA1 transcription.
2003 Jul 18
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.
2003 Jul 7
Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis.
2003 Jun
Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens.
2003 Jun
Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
2003 Jun
Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate.
2003 Jun 15
Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate.
2003 Mar 15
Effects of ibandronate on inflammation in mouse antigen-induced arthritis.
2003 May
Ibandronate: new options in the treatment of osteoporosis.
2003 Nov
Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth.
2003 Nov 10
Bisphosphonates in children with bone diseases.
2003 Nov 20
Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples.
2003 Nov 3
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
2003 Oct
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.
2003 Oct
The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status.
2003 Oct
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
2003 Oct
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
2003 Sep
The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats.
2003 Sep 30
Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
2004 Apr
[Ibandronate].
2004 Feb
Effect of augmentation cystoplasty on bone metabolism in chronic uremic rats.
2004 Feb
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
2004 Jan
Hypercalcemia of malignancy.
2004 Jan
Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat.
2004 Jan 16
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
2004 Mar
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.
2004 Mar
Nephrotoxicity of third-generation, intravenous bisphosphonates.
2004 Mar 1
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
2004 Mar 22
Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.
2004 May
Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells.
2004 May
Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats.
2004 May
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
2004 Oct
Patents

Patents

JP2006519264A
58
JP4708327B2
47

Sample Use Guides

In Vivo Use Guide
Oral: 150 mg orally once a month on the same day each month IV Injection: 3 mg by IV injection over 15 to 30 seconds every three months.
Route of Administration: Other
In Vitro Use Guide
Cells were cultivated in cell culture flasks at 37_Cand5%CO2. The culture media were as recommended by the American Type Culture Collection (ATCC) for MDA-MB-231 breast cancer DMEM (Sigma-Aldrich, St. Louis, MO, USA), which contained 10% fetal calf serum (FCS); PC-3 prostate carcinoma DMEM-F12 (Sigma-Aldrich) with 10% FCS. MG-63 and U2-OS osteosarcoma were cultured in AlphaMEM (Biochrom, Berlin, Germany) medium containing 10% FBS. For the HMC1.1 cell line, we used Iscove’s Modified Dulbecco’s Medium (IMDM; Thermo Fisher Scientific, Waltham, MA) supplemented with 260 nM thioglycerol (Sigma-Aldrich) and20%fetal bovine serum (FBS). All culture media contained 10 mg/mL gentamycin (Sigma-Aldrich). To guarantee optimal growth, cells were split two times a week and reseeded at a density of 2-5 x 105 cells/mL. One day after splitting, 32 mMsimvastatin (Sigma-Aldrich) or 150 mM ibandronate (Sigma-Aldrich) were added to the culture medium for 72 hours. This is the dose that attenuated cell proliferation with a half maximal effect. NADP/NADPH analyses were performed directly in 96-well culture plates after 24 or 48 hours
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:57:11 GMT 2023
Edited
by admin
on Sat Dec 16 15:57:11 GMT 2023
Record UNII
UMD7G2653W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IBANDRONIC ACID
EMA EPAR   INN   MART.   MI   WHO-DD  
INN  
Official Name English
IBANDRONATE [VANDF]
Common Name English
IBANDRONIC ACID ACCORD
Brand Name English
NSC-722623
Code English
Ibandronic acid [WHO-DD]
Common Name English
IBANDRONIC ACID [EMA EPAR]
Common Name English
IBANDRONIC ACID [MART.]
Common Name English
IASIBON
Brand Name English
IBANDRONATE
VANDF  
Common Name English
BONDENZA
Brand Name English
(1-HYDROXY-3-(METHYLPENTYLAMINO)PROPYLIDENE)DIPHOSPHONIC ACID
Systematic Name English
IBANDRONIC ACID [MI]
Common Name English
IBANDRONIC ACID SANDOZ
Brand Name English
ibandronic acid [INN]
Common Name English
IBANDRONIC ACID TEVA
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS BONDRONAT (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
NCI_THESAURUS C67439
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID TEVA (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS BONDENZA (WITHDRAWN: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
NCI_THESAURUS C443
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID TEVA (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IASIBON (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS HALAVEN (AUTHORIZED: BREAST NEOLPLASMA)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID SANDOZ (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID ACCORD (AUTHORIZED: WOUNDS AND INJURIES)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
NDF-RT N0000007707
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
WHO-VATC QM05BA06
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS BONVIVA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID ACCORD (AUTHORIZED: NEOPLASTIC PROCESSES)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS DESTARA (WITHDRAWN: CANCER, HYPERCALCIMA)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID SANDOZ (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
WHO-ATC M05BA06
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
LIVERTOX 494
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID TEVA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS IASIBON (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS XGEVA (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
NDF-RT N0000175579
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
EMA ASSESSMENT REPORTS BONDRONAT (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL997
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID5048340
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
MERCK INDEX
m6182
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY Merck Index
FDA UNII
UMD7G2653W
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
RXCUI
115264
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
ALTERNATIVE
IUPHAR
3059
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
NCI_THESAURUS
C65874
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
MESH
C073007
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
DRUG CENTRAL
1404
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
WIKIPEDIA
IBANDRONIC ACID
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
NSC
722623
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
SMS_ID
100000085439
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
EVMPD
SUB08092MIG
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
RXCUI
115265
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
DRUG BANK
DB00710
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
PUBCHEM
60852
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
INN
7189
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
DAILYMED
UMD7G2653W
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
CAS
114084-78-5
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
LACTMED
Ibandronate
Created by admin on Sat Dec 16 15:57:12 GMT 2023 , Edited by admin on Sat Dec 16 15:57:12 GMT 2023
PRIMARY
Related Record Type Details
Structure of IBANDRONIC ACID
EXCRETED UNCHANGED
The portion of ibandronate that is not removed from the circulation via bone absorption is eliminated unchanged by the kidney (approximately 50% to 60% of the absorbed dose). Unabsorbed ibandronate is eliminated unchanged in the feces.
FARNESYL PYROPHOSPHATE SYNTHASE
TARGET -> INHIBITOR
Structure of IBANDRONATE SODIUM
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.
BINDING
GERANYLGERANYL PYROPHOSPHATE SYNTHASE
TARGET -> INHIBITOR
Related Record Type Details
Structure of IBANDRONIC ACID
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC DOSE

ORAL ADMINISTRATION

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966